Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONO-7702/7703-03: ONO-7702/ONO-7703 Phase II study Phase II of combination therapy with ONO-7702 and ONO-7703 for unresectable thyroid cancer with BRAF V600 gene mutation Phase test

Next Previous
Search
Trial Profile

ONO-7702/7703-03: ONO-7702/ONO-7703 Phase II study Phase II of combination therapy with ONO-7702 and ONO-7703 for unresectable thyroid cancer with BRAF V600 gene mutation Phase test

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Encorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Ono Pharmaceutical

    • Most Recent Events

    • 01 Apr 2024 Results (At data cutoff (October 26, 2022) assessing efficacy and safety of a BRAF inhibitor, encorafenib, combined with an MEK inhibitor, binimetinib, in patients with BRAF V600-mutated thyroid cancer published in the Thyroid
    • 08 Jun 2023 New trial record
    • 31 May 2023 According to an Ono Pharmaceutical media release, based on the data of this study, the company has submitted supplemental applications for approval of BRAFTOVI (encorafenib) Capsule and MEKTOVI (binimetinib) Tablet, in Japan for the treatment of radically unresectable BRAF-mutant thyroid cancer, in doublet combination therapy with BRAFTOVI and MEKTOVI.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top